FDA stalls Eisai—and its new partner Merck—in quest to widen cancer med Lenvima's reach

Merck & Co. was expecting big things from Eisai’s Lenvima in March, when it agreed to shell out up to $5.8 billion on half of the liver cancer drug’s sales. But in the first expansion bid since that deal, Lenvima has hit a snag.